Outcomes Of Surfactant Therapy In Newborns With Respiratory Distress Syndrome In Relation To Age Of Presentation To NICU Of MGM Hospital
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 2686-2696
AbstractBACKGROUND:RDS is usually defined by the presence of acute respiratory distress with disturbed gas exchange in a preterm infant with a typical clinical course or x-ray.The main risk factor for RDS,by far,is prematurity.The central feature of RDS is surfactant deficiency due to lung immaturity,commonly due to prematurity.Surfactant replacement therapy reduces mortality and several aspects of morbidity in babies with RDS.
METHODS:Newborns with RDS were intubated with endotracheal tube and surfactant was administered.The first dose of surfactant was given as early as possible to the preterm infants requiring MV for RDS then extubated and connected to nasal CPAP.The mortality,morbidities were compared.
RESULTS:Among the 150 preterms who were recruited in this study, outcomes of surfactant therapy is discussed in correlation with the time of presenation,hour of installation of surfactant,birth weight,gestational age,size for gestational age, severity of RDS,surfactant doses,length of hospital stay,type of assisted ventilation,duration of assisted ventilation,duration of supplemental oxygen,complications with surfactant therapy.We found that surfactant replacement therapy has a beneficial effect.
CONCLUSION:Out of 150 preterms with RDS who are more than 31 weeks of gestation,more than 1500 grams,appropriate for gestational age,Singleton neonates,mild and moderate respiratory distress,and who received single dose of surfactant with RDS, had better outcome and discharged.45.3% of the preterm new born who were given surfactant had fatal outcome.Only 54.7% of preterm newborns who were given surfactant have discharged.
- Article View: 9
- PDF Download: 21